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1. Introduction 
The contribution of the immune system to the pathogenesis of chronic lymphocytic 
leukemia (CLL) is receiving increasing attention in recent years. This interest has been 
supported by population studies, which have shown the increase of cancer risk in 
immunodeficient individuals (Grulich et al., 2007; Smyth et al., 2006; Swann et al., 2007), and 
experimental studies, which have shown that deficiencies in key immunological molecules 
and cells increase the susceptibility to develop several types of solid tumors and 
hematological malignancies (Smyth et al., 2006; Swann et al., 2007). Additionally, the interest 
in the study of tumor immunology has been boosted by the increasing use of 
immunotherapy in the treatment of cancer, particularly in CLL. In this chapter, we review 
the role of the immune system in the elimination of CLL, the mechanisms that leukemia cells 
use to evade the immune response, and finally, we analyze the basis of the use of 
immunotherapy in the treatment of CLL patients. 
2. Immune surveillance of cancer 
The immune system is able to prevent cancer development by eliminating cancer cells 
prior to tumors becoming clinically detectable or by attenuating tumor growth and 
progression (Smyth et al., 2006; Swann et al., 2009). Both T cells and Natural Killer (NK) 
cells play a critical role in cancer immune surveillance (Figure 1). T cells are able to 
recognize tumor antigens, which differentiate cancer cells from their nontransformed 
counterparts. Several tumor antigens have been described such as mutation of oncogenic 
proteins (e.g. p53), over-expressed cellular antigens (such as HER-2), viral antigens, 
differentiation antigens and aberrantly expressed antigens (Smyth et al., 2006; Swann et al., 
2007). Cytotoxic CD8 T cells and helper CD4 T cells may recognize transformed cells 
bearing these tumor antigens presented as peptides by MHC class I and class II molecules, 
respectively.  
www.intechopen.com




Fig. 1. Mechanisms of cancer immune surveillance. T Cell Receptor (TCR) expressed by CD8 
T cells is able to recognize tumor antigens presented as peptides by the Major 
Histocompatibility Complex class I proteins (MHC-I) (nonself recognition). NK cells use 
several mechanisms to recognize tumor cells. NK cells use inhibitory receptors to 
differentiate “self” from “missing self”. The impairment of MHC class I expression observed 
in some tumor cells impairs the recognition by CD8 T cells. Nevertheless, MHC class I 
molecules have an inhibitory effect on the activation of NK cells. Consequently, the lack of 
expression of MHC class I molecules (missing self) promotes the activation of NK cells and 
the lysis of the target cell. NK cells also express activating receptors, such as NKG2D, which 
is able to recognize several ligands induced in transformed cells (induced self). NK cells also 
express the FcǄRIII receptor (also named CD16), which is able to recognize tumor cells that 
have been bound by specific IgG antibodies. This mechanism of recognition is termed 
Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC). 
NK cells do not directly recognize tumor antigens, but instead, they recognize changes in 
cells caused by transformation. Several mechanisms of cancer recognition by NK cells have 
been described (Gonzalez et al., 2011). NK cells use a set of inhibitory receptors, such as  
killer cell immunoglobulin-like receptors (KIRs), to differentiate and eliminate cancer cells 
that lack MHC class I expression (“missing self” recognition) (Figure 1) (Gonzalez et al., 
2011). NK cells also express activating receptors which recognize stress-induced molecules 
expressed on tumor cells (“induced self” recognition). The activating receptor NKG2D plays 
a pivotal role in the immune response against cancer. This receptor is expressed by NK cells, 
T cells and CD8 T cells, and recognizes several tumor-associated ligands named MICA, 
MICB and ULBP1-5 molecules. NKG2D ligands are restrictedly expressed in healthy cells, 
but they are induced in stressed and transformed cells, allowing the elimination of these 
cells by the immune system (Das et al., 2001; Raulet et al., 2003; Bauer et al., 1999; Lopez-
Larrea et al., 2008; Bahram et al., 1994 ; Cosman et al., 2001; González et al., 2008; Guerra et 
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al., 2008). NK cells may also lyse target cells that have been bound by specific IgG 
antibodies. They are able to recognize the Fc region of the antibody through FcǄRIII receptor 
(also named CD16). This mechanism of recognition is termed Antibody-Dependent Cell-
Mediated Cytotoxicity (ADCC) and it is an important mechanism of action against tumors 
of therapeutic monoclonal antibodies, such as rituximab and alemtuzumab (Figure 1). These 
mechanisms of anti-tumor immune response may protect the host in the early stages of 
tumor initiation; however during cancer progression, tumors develop a plethora of 
mechanisms of immune evasion. Consequently, the anti-tumor response is ineffective in 
advanced tumors (Smyth et al., 2006; Swann et al., 2007). 
3. Immune surveillance of chronic lymphocytic leukemia 
There is little information related to the role of the immune response in the early stages of 
CLL progression. Nevertheless, it has widely been reported that the amounts of CD8 and 
CD4 T cells and NK cells are significantly elevated at diagnosis of the disease. The 
expansion of cytotoxic CD8 T cells is higher than CD4 T cells, and many CLL patients 
showed an inversion of CD4/CD8 ratio (Gonzalez-Rodriguez et al., 2010). Similar 
expansions of immune cells have been observed in other hematological malignancies and 
this increase of immune cells has been associated with a better prognosis of patients. Thus, 
higher absolute lymphocyte count predicts higher survival in lymphoma, acute myeloblastic 
leukemia and myeloma (Cox et al., 2008; Siddiqui et al., 2006; Porrata et al., 2007, 2009; Ray-
Coquard et al., 2009; De Angulo et al., 2008; Behl et al. 2006, 2007; Ege et al., 2008). NK cell 
count has also been associated with clinical outcome in patients with diffuse large B-cell 
lymphoma (Plonquet et al., 2007). The expansion of immune cells observed in CLL and in 
other hematological malignancies may be compared to the expansion of tumor infiltrating 
lymphocytes in epithelial tumors. In several types of cancer, the presence of tumor 
infiltrating lymphocytes, mainly NK and CD8 T cells, has also been associated with the anti-
tumor response and was found to be a better predictor of patient survival than traditional 
histopathological methods used to stage tumors (Dunn  et al., 2004; Clemente et al., 1996; 
Scanlan et al., 2004; Rollins et al., 2006; Moore OS et al., 1949; Clark et al., 1969; Pagès et al., 
2005) 
In agreement with an anti-tumor role of the immune system, the expansion of NK and T 
cells has been associated with the time to treatment in CLL (Palmer et al., 2008). 
Furthermore, the relative numbers of CD8 and CD4 T cells at diagnosis are independent 
predictors for survival, and higher CD8 count is associated with significantly higher median 
time of survival of CLL patients (Gonzalez-Rodriguez et al., 2010). This suggests that the 
expansion of immune cells observed at diagnosis of CLL patients may be due, at least in 
part, to the expansion of anti-tumor immune cells. However, the analysis of the functionality 
of these cells is still lacking. Early studies showed that the expanded CD8 T cells have an 
activated phenotype and cytotoxic function and appear to have restricted clonality, which 
were originally interpreted as evidence of an autologous T cell response against leukemia 
cells. Furthermore, a subset of ǄǅT cells with anti-tumor activity is one type of the immune 
cells expanded in CLL patients (Poggi et al., 2004). These T cells express the activating 
receptor NKG2D, which is able to mediate the lysis of CLL cells expressing NKG2D ligands 
(“induced self” recognition) (Figure 1). Leukemia cells from most patients lack NKG2D 
ligands expression and are highly resistant to NK cell-mediated lysis, but NKG2D ligands 
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expression may be induced in leukemia cells by treatment with trans-retinoic acid or histone 
deacetilases (HDACs) inhibitors, rendering leukemia cells susceptible to lysis by immune 
cells (Kato et al., 2007; Del Giudice et al., 2009). The expansion of ǄǅT cells has been 
associated with a better prognosis of CLL patients, supporting the hypothesis that the 
increase of T cells observed at diagnosis of CLL patients may be due, at least in part, to the 
expansion of anti-tumor T cells.  
The activation of the immune system in CLL patients has not only been associated with 
improved prognosis, but also with tumor regression. The natural history of stage A disease 
is generally indolent or only slowly progressive. However, it is less known that CLL may 
undergo spontaneous regression (Del Giudice et al., 2009). There are no data about the 
functional role of the immune system in these remissions; however the activation of immune 
system has been associated with spontaneous remissions in other types of cancers (Smyth et 
al., 2006; Swann et al., 2007). This suggests that the activation of the anti-tumor immune 
response may have a significant impact on the progression of CLL, however further 
analyses about the functionality of immune cells in CLL are clearly warranted. 
The role of immune system in CLL is further highlighted by the analysis of cancer risk in 
immunodeficient individuals. However, the deficiency of CD8 T cells is not compatible with 
life and most of the studies about the role of other immune deficiencies on cancer susceptibility 
are nonpopulation-based and of small sample size, making difficult to draw definite 
conclusions. Nevertheless, primary immune deficiency patients have been associated with a 
marked increased risk of cancer. Some types of cancers appear to be associated with specific 
forms of immunodeficiency including stomach cancer with common variable immune 
deficiency (CVID) (Kinlen et al., 1985; Mellemkjaer et al., 2002), leukemia with ataxia-
telangiectasia (Morrell et al., 1986), and nonmelanocytic skin cancer with cartilage-hair 
hypoplasia (Taskinen et al., 2008). In a recent population-based study, the association of 
antibody deficiency with an increasing risk of leukemia, non-Hodgkin lymphoma and gastric 
cancer has been described (Vajdic et al., 2010). In agreement with clinical data, deficiencies in T 
cells and NK cells have also been associated with increased susceptibility of cancer in a 
diversity of experimental models of cancer (Smyth et al., 2006; Swann et al., 2007). 
Nevertheless, the most compelling evidence about the potential role of the immune system 
in the pathogenesis of CLL is the increasing use of immunotherapy in the treatment of this 
disease. This highlights the capacity of the activation of the immune system to eliminate 
CLL cells and the potential role of immune system to cure this disease. Thus, the therapeutic 
effect of allogeneic hematopoietic stem cell transplantation in CLL relies on the ability of the 
immune cells of the graft to recognize and eliminate leukemia cells (Mehta et al., 1996; 
Ritgen et al., 2008). Similarly, the therapeutic use of immunomodulatory drugs, such as 
lenalidomide, is not directly based on a cytotoxic effect on CLL cells, but instead, 
lenalidomide exerts its therapeutic effect through the stimulation of the immune system.  
4. Immune defects in chronic lymphocytic leukemia patients 
In spite of the existence of compelling evidences about the ability of the immune system to 
eliminate nascent tumors, when the immune system is unable to eliminate all cancer cells, it 
sculpts or edits the phenotype of cancer cells, eliminating the most immunogenic ones and 
selecting the less immunogenic tumor cells, which are able to evade or suppress the immune 
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response. The consequence of this process, named cancer immunoediting, is the 
development of numerous mechanisms of immune evasion and immune suppression in 
advanced tumors (Smyth et al., 2006; Swann et al., 2007). Accordingly, there is a progressive 
acquisition of a wide variety of immune defects in the course of the progression of CLL. As a 
result, patients progressively acquire a immunodeficiency status, which increases the 
incidence of opportunistic infections and the development of secondary neoplasias 
(Hamblin et al., 2008). The corollary of immune defects also includes the development of 
several autoimmune reactions. CLL patients have a 5-10% risk of development of an 
autoimmune complication, which primarily cause cytopaenia (Zent et al., 2010). The most 
common autoimmune disease affecting CLL patients is hemolytic anemia, with a lower 
frequency of immune thrombocytopenia and pure red blood cell aplasia and only rarely, 
autoimmune granulocytopaenia. 
Practically all components of the immune system are impaired in CLL patients. The most 
obvious and well-known immune defect is hypogammaglobulinemia, which is present in up 
to 85% of patients (Hamblin et al., 1987). Hypogammaglobulinemia is observed in other 
lymphoid malignancies, but the impairment of the humoral immune response is far greater 
in CLL. The clinical consequence of hypogammaglobulinemia is the increase of 
susceptibility of CLL patients to infection with extracellular bacterias, commonly affecting 
respiratory tract, skin and urinary tract, and the reactivation of some latent virus infections, 
mainly belonging to Herpesviridae family.  
The defects in the humoral immunity are accompanied by several abnormalities in the 
cellular immune response, including quantitative and qualitative alterations of NK cells, 
CD4 and CD8 T cells, dendritic cells, neutrophils, monocytes and cytokines. The activity of 
NK cells against leukemia cells is frequently reduced and lymphoid neoplasms are quite 
resistant to NK cell-mediated cytotoxicity (Foa et al., 1984; Jewell et al., 1992; Kato et al., 
2007). All effector mechanisms of NK cells analyzed are impaired in some degree in 
advanced CLL patients (Katrinakis et al., 1996; Caligaris-Cappio et al., 1999; Wierda et al., 
1999). A partial down-regulation of MHC class I molecules, which allow leukemic cells to 
escape from cytotoxic T cell attack, has been reported (Demanet et al., 2004). However, the 
“missing self” recognition by NK cells (Figure 1) is limited in CLL by the aberrant 
expression of HLA-G in leukemia cells. HLA-G is a non classical MHC class I molecule that 
is physiologically expressed on fetal derived placental cells. Classical MHC class I molecules 
(HLA-A, -B and -C) are not expressed in fetal placental cells, but HLA-G inhibits NK cells 
activation against placental cells by interacting with several inhibitory receptors expressed 
by NK cells and cytotoxic T lymphocytes. Likewise, the aberrant expression of HLA-G on 
leukemia cells impairs the anti-leukemia immune response mediated by these cells. 
Accordingly, the expression of HLA-G on leukemia cells correlated with progression free 
survival and the level of immunosuppression of CLL patients (Nückel et al., 2005; Erikci et 
al., 2009).  
There are also defects on the expression of NKG2D and its ligands in CLL (Gasser et al., 2005; 
Groh et al., 1996, 1999; Diefenbach et al., 2001; Cerwenka et al., 2001; González et al., 2006). The 
expression of NKG2D ligands in leukemia cells is low or absent in most of patients, which 
confers them with a high resistance to lysis by immune cells (Poggi et al., 2004). Furthermore, 
leukemia cells may also counter the anti-tumor activity of NKG2D by shedding some of its 
soluble ligands. Serum levels of soluble MICA, MICB and ULBP2 are significantly increased in 
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CLL patients and are associated with a poor treatment-free survival (Nückel et al., 2010). The 
shedding of soluble MICA has been described in many types of cancer and elevated levels of 
soluble MICA correlated with advanced stage tumors, metastasis and poor prognosis (Salih et 
al. 2002, 2003; Raffaghello et al., 2004; Rebmann et al., 2007), because soluble MICA impairs the 
recognition of cancer cells by immune cells and suppress the immune response (Groh et al., 
2002, 2006). Of relevance, some of the immune defects observed in CLL patients may be 
reversible. For instance, leukemia cells which express low levels of NKG2D ligands may be 
rendered susceptible to immune cells when are treated with trans-retinoic acid or histone 
deacetylase inhibitors inhibitors, which restored the expression of NKG2D ligands on 
leukemia cells (Salih et al., 2002). This clearly suggests that therapeutic approaches that can 
bypass the immune evasion mechanisms of CLL patients may have therapeutic application in 
this disease.   
T cell function is also impaired in CLL. There are defects on antigen presentation (Cantwell 
et al., 1997), T cell activation, in differentiation and function of CD4 T cells and defects in the 
cytotoxic activity of CD8 cells that are caused by direct contact with leukemia cells (Gorgun 
et al., 2005; Rossi et al., 1996; Junevik et al., 2007; Mackus et al., 2003). Regulatory T cells, a 
specialized subpopulation of T cells which suppresses the activation of the immune system 
and thereby maintains tolerance to self antigens, are increased in number in CLL and this 
increase is more significantly in most advanced patients (Beyer et al., 2006). It is not yet clear 
whether inhibitory T cells may promote the tolerance of leukemia cells by the immune 
system and may contribute to the immune deficiency. Nevertheless, it is noticeable that this 
population is exquisitely sensitive to treatment with fludarabine. It has been proposed that 
the elimination of these inhibitory T cells might be one of the mechanisms that favors the 
development of autoimmune hemolytic anemia after treatment of CLL patients with 
fludarabine (Hamblin et al., 2006).  
The defects of cellular immunity observed in CLL increase the susceptibility of patients to 
virus infections, opportunistic infections and second malignancies, and may contribute to 
impair the anti-leukemia immune response. Additionally, the use of chemotherapy agents 
may complicate the clinical course of CLL since may exacerbate the pre-existing 
immunodeficiency. Nevertheless, the development of drugs and therapeutic strategies that 
can either bypass immune evasion mechanisms or rescue immune suppressor pathways 
may significantly benefit CLL patients. Thus, the increasing understanding of the molecular 
and cellular events underlying the immune dysfunction in CLL is of key importance in the 
development of novel immune-based therapies. 
5. Immunotherapy 
CLL is generally considered as an incurable disease, but it frequently progresses slowly. 
Early-stage CLL is, in general, not treated since there are no clear evidences that early 
therapeutic intervention improves survival time or quality of life. Instead, the disease is 
monitored over time to detect changes in disease progression. Determining when to start 
the treatment and by what means is often difficult. The National Cancer Institute Working 
Group has issued guidelines for treatment (Cheson et al., 1996; Hallek et al., 1996). 
Until recently, chemotherapy has been the keystone of treatment of CLL. Alkylating agents 
have been considered the first line in the treatment of CLL patients for a long time. They can 
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induce complete responses, but it is not considered curative. Chlorambucil slows disease 
progression, but does not prolong survival (Dighiero et al., 1998; Eichhorst et al., 2006; 
Hallek, 2010) (Figure 2). The purine analogue fludarabine was shown to give superior 
response rates to chlorambucil as primary therapy (Steurer et al., 2006; Rai et al., 2000), but 
there are no evidences that the early use of fludarabine improves overall survival. Treatment 
combinations of Fludarabine with the alkylating agent Cyclophosphamide (FC) result in 
higher response rates, in longer median progression-free survival and longer treatment-free 
survival than single agents (Maloney et al., 1999). Thus far, no difference in median overall 
survival has been observed. 
 
Fig. 2. Chronic lymphocytic leukemia therapy. The figure shows rates of complete 
remissions and overall response in CLL first line treatment. (F=Fludarabine, 
C=Cyclophosphamide, R= Rituximab).  
In spite of the fact that chemotherapy provides benefits for CLL patients, it is palliative, and 
treated patients frequently develop recurrent disease. Likewise treatment induces 
myelosuppression and selection of chemotherapy resistant clones. Additionally, it can 
worsen immune function, increasing the immunodeficiency status of CLL patients. 
Prognosis for patients treated with chemotherapy regimens remains poor, prompting the 
development of new targeted agents. In line with this idea, the activation of the immune 
system to fight against CLL cells has opened new vistas in the treatment of CLL. 
Immunotherapy may potentially provide curative treatment and some immunotherapeutic 
approaches may mitigate disease complications caused by the defects of the immune system 
observed in CLL patients. In this sense, monoclonal antibodies, allogeneic hematopoietic 
stem cell transplantation and immunomodulatory drugs have successfully been used in the 
treatment of CLL. Immune-based therapy represents an exciting mode of treatment since it 
may be able to eliminate leukemia cells without myelosuppression.  
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5.1 Monoclonal antibodies 
Monoclonal antibodies have the ability to target specific antigens expressed preferentially 
on the surface of malignant cells. Due to their specificity, the therapeutic efficacy of 
monoclonal antibodies is not generally associated with a high non-specific toxicity. Thus, 
they are increasingly being used in the treatment of hematological malignancies and solid 
tumors. In CLL, the use of rituximab, a chimeric murine/human monoclonal antibody 
directed against CD20, has improved the treatment of patients. Unlike other B cells antigens, 
CD20 is neither shedded nor internalized in resting normal B cells. Therefore it is an ideal 
target for antibody-based therapy in mature B cell malignancies. Rituximab treatment 
induces a significant reduction in B cell count within 3 days followed by a slow recovery 
over 9-12 months (Maloney et al., 1997; Onrust et al., 1999). The mechanism of B cell killing 
has not completely been elucidated, but rituximab acts through Antibody-Dependent Cell-
Mediated Cytotoxicity, complement-mediated cytotoxicity, the activation of macrophages, 
and direct apoptosis of leukemia cells both caspase dependent and independent (Jaglowski  












      complex
 
Fig. 3. Mechanism of action of rituximab. Rituximab is a monoclonal antibody directed 
against CD20 antigen, which is expressed on the surface of B cells. The recognition of the Fc 
portion of rituximab through the FcǄRIII receptor mediates the lysis of leukemia cells by NK 
cells; a process named Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC). The Fc 
portion of rituximab also induces the activation of the classical pathway of complement. The 
activation of complement cascade forms a transmembrane channel, which causes the 
osmotic lysis of the leukemia cell. Rituximab may also cause a direct apoptosis of CD20 cells. 
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The efficacy of rituximab monotherapy in CLL is lower than in other B cell malignancies. 
The resistance to rituximab is frequently associated with a low CD20 expression. 
Nevertheless, the addition of rituximab to chemotherapy has proven to be very efficacious 
therapy for CLL. Treatment combinations of Fludarabine, Cyclophosphamide and 
Rituximab (FCR) obtain the highest response, but they are not still considered curative (Byrd 
et al., 2005; Tam et al., 2008; Wierda et al., 2005) (Figure 2). FCR therapy shows superiority 
for response rates and progression-free survival when compared to FC chemotherapy 
(Hallek et al., 2009; Robak et al., 2008), and it is becoming the first-line choice for younger 
patients (Casak et al., 2011). Additionally, rituximab represents one of the most active 
therapies for the treatment of autoimmune complications of CLL not responding to initial 
steroid treatment. The use of monoclonal antibodies for purging of leukemia cells ex vivo 
also improves the results of autologous stem cell transplantation (Gribben et al., 2005; 
Montillo et al., 2006). 
The therapeutic efficacy of rituximab is minimally hampered by non-specific toxicity; 
however it has been associated with adverse events such as immunosuppression, 
reactivation of latent virus and infusion-related. Combination with chemotherapy may be 
associated with more profound immunosuppression. Management of these adverse events 
is a critical component of the treatment strategy for CLL since they can greatly affect the 
quality of life of patients and the ability to tolerate this therapy. 
Alemtuzumab, a CD52-target humanized monoclonal antibody, has demonstrated benefits 
in the treatment of CLL patients (Gribben et al., 2009). CD52 is a protein highly expressed on 
both normal and malignant lymphocytes (B and T cells) and it is also found in other 
immune cells such as monocytes, macrophages and eosinophils; but it is not expressed on 
hematopoietic progenitors. The administration of alemtuzumab results in a severe 
lymphopenia with a reduction in both B and T cells, but it also affects other healthy CD52-
expressing immune cells, which likely exacerbate the pre-existing immunodeficiency. After 
treatment, there is a slow recovery of immune cells, except for B cells, which remain at low 
level at 18 months. Alemtuzumab acts through Antibody-Dependent Cell-Mediated 
Cytotoxicity (Crowe et al., 1992) (Figure 1), complement-mediated cytotoxicity (Golay et al., 
2004; Zent et al., 2004), and induces direct cell death through a mechanism that is 
independent of p53 status and caspase activation (Mone et al., 2006), and is effective in 
patients with deletion (17p)(13.1).  
A significant difference between the efficacy of alemtuzumab and rituximab is based on the 
fact that the level of CD52 expression in normal and malignant B cells is far greater than the 
level of CD20 expression in CLL cells. The high expression of CD52 may contribute to the 
improved clinical activity of alemtuzumab as a single-agent compared to rituximab in CLL 
(Ashraf et al., 2007). Alemtuzumab is currently approved for first-line treatment of CLL, and 
it is a good option for symptomatic patients, previously untreated patients and relapsed 
patients with poor prognostic features (Keating et al., 2002; Osterborg et al., 1996; Lundin et 
al., 2002 ; Hillmen  et al., 2007). 
New monoclonal antibodies directed against CD20, such as ofatumumab and GA101, have 
been developed. Ofatumumab and rituximab bind to different epitopes, and, in theory, 
ofatumumab has greater capacity of activation of complement-dependent cytotoxicity than 
rituximab (Teeling et al., 2004). In vitro studies have demonstrated that ofatumumab is 
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significantly more effective than rituximab at lysing CLL cells and B cell lines, especially 
those with low CD20 copy numbers. It is currently approved for treating CLL patients who 
are refractory to fludarabine and alemtuzumab.  
The novel third generation humanized monoclonal antibody GA101 also binds with high 
affinity to CD20, and as a result it promotes greater induction of Antibody-Dependent Cell-
Mediated Cytotoxicity (Jaglowski et al., 2010) and induces more efficient NK cell activation 
than rituximab (Bologna et al., 2011). The development of new monoclonal antibodies is 
probably the best demonstration of the therapeutic efficacy that these agents have obtained 
in CLL and other hematological malignancies.  
5.2 Hematopoietic stem cell transplantation 
About 20% of patients who need treatment develop an aggressive disease despite early 
institution of intensive chemotherapy. Efforts to develop curative treatment for these CLL 
patients have focused on autologous and allogeneic hematopoietic stem cell transplantation 
(Dreger et al., 2009). Both approaches show some methodological similarities, but the bases of 
both treatments are significantly different. Most patients may achieve a complete molecular 
response followed by autologous stem cell transplantation, a lower-risk form of treatment 
using the patient's own blood cells, which restores the hematopoietic system after an intensive 
chemotherapy regimen. The increase of the dose chemotherapy regimen is the base of the 
efficacy of autografting, and consequently, it is not an immune-based therapy. This therapy is 
not curative and subsequent clinical progression is inevitable (Provan et al., 1996; Milligan et 
al., 2005). The results of a phase 3 randomized European Group for Blood and Marrow 
Transplantation trial of autologous stem cell transplantation show the reduction of the risk of 
progression of CLL by more than 50%, but it does not have an effect on overall survival 
(Michallet et al., 2011), and it is particularly concerning the high incidence of myelodysplastic 
syndrome (9-12%) (Kharfan-Dabaja et al., 2007). Therefore, it is necessary to look for other 
solutions of treatment in this disease different from the chemotherapy and to move toward 
alternative non-chemotherapy-based treatment approaches. 
Allogeneic stem cell transplantation offers a chance of definite cure of CLL, but is only 
feasible in a minority of patients. The basis of therapeutic response of allogeneic stem cell 
transplantation relies on the ability of immune cells of the graft to recognize and eliminate 
leukemia cells, a process known as graft-versus-leukemia effect (GvL) (Mehta et al., 1996; 
Ritgen et al., 2008) (Figure 4). Thus, allogeneic stem cell transplantation is a cellular-based 
immunotherapy completely different from autografting. The immunology of allogeneic 
stem cell transplantation is different from other types of transplants, such as heart or kidney 
transplants, because the graft, in addition to stem cells, contains and generates mature 
immune cells including T cells, NK cells and dendritic cells. These cells repopulate the 
recipient’s immune system, restoring the response to infections and eliminating leukemia 
cells. The donor immune cells exert its graft-versus-leukemia effect through T cell-mediated 
alloreaction against the histocompatibility antigens displayed on leukemia cells. However, 
as histocompatibility antigens are shared by all cells of individual, recipient tissues may also 
be attacked by donor’s immune system causing graft-versus-host-disease (GvHD) 
(rejection), a life-threatening condition. For this reason, matching donor and recipient HLA 
molecules is crucial to minimize graft-versus-host-disease. Mismatches in HLA-A, -B, -C 
and HLA class II alleles are significant risk factors for graft-versus-host-disease. Due to the 
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high number of HLA alleles is quite difficult to find a HLA-matched unrelated donor, but 
nearly 25% of siblings share both HLA haplotypes, because all HLA genes are closely linked 
in a small region of chromosome 6, known as Major Histocompatibility Complex (MHC). 
However, even in HLA-matched recipient and donor, graft-versus-host-disease may occur 
due to minor histocompatibility antigens, which are derived from differences between 
donor and recipient in other polymorphic genes different from HLA, differences in the level 
of expression of proteins or are derived from genome differences between male and female 
(such as H-Y antigens encoded by Y chromosome, which is absent in females). 
 
Fig. 4. Allogeneic stem cell transplantation. Hematopoietic stem cells are collected from the 
bone marrow or blood of the donor. Bone marrow or blood is taken to the processing 
laboratory where stem cells are concentrated and may be freezed (cryopreservation). High 
dose chemotherapy and/or radiation are given to the patient. To restore the patient’s 
immune system, thawed or fresh stem cells are infused into the patient. The donor immune 
cells eliminate leukemia cells (graft-versus-leukemia) through a T cell-mediated alloreaction 
against patient’s histocompatibility antigens displayed on leukemia cells. 
If a HLA-matched sibling is not available, the use of unrelated umbilical blood units or an 
unrelated matched donor are viable options. Umbilical blood units offer the advantage that 
a higher number of mismatches in HLA antigens does not preclude transplant feasibility 
since naïve T cells in cord blood are less able to cause graft-versus-host-disease than mature 
donor T cells in bone marrow or peripheral blood, however graft-versus-leukemia is also 
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less intense. Family donors, who matched a HLA haplotype, but fully mismatched the other 
(“haploidentical”) is another option to obtain hemopoietic stem cells. The haploidentical 
transplant recipients have high risk of T-cell mediated graft-versus-host-disease (Velardi et 
al., 2010). This is controlled by an extensive immunosuppressive intensity in the 
conditioning regimen and extensive T cell depletion of the graft to prevent graft-versus-
host-disease. The immune suppression and the depletion of T cells might be expected to 
result in weak or no graft-versus-leukemia effect, as it is conventionally achieved through T 
cell-mediated alloreactivity directed against recipient’s histocompatibility antigens. 
Surprisingly, another immune cell influences the outcome of allogeneic stem cell 
transplantation in a favorable way. In these transplants, NK cell-mediated alloreactivity may 
control leukemia relapse without causing graft-versus-host-disease. This alloreaction is due 
to the fact that NK cells express specific inhibitory receptors, such as KIR or CD94/NKG2, 
for groups of HLA class I alleles. Inhibitory receptors and HLA class I genes structure 
individual NK cell repertoires during development. To establish a self-tolerance, each 
individual selects NK cells carrying inhibitory receptor combinations for their self HLA class 
I molecules. NK cells from those individuals that express inhibitory receptors for a HLA 
class I group, which is absent on allogeneic transplants, sense the missing expression of their 
self HLA class I molecules and mediate alloreactions against leukemia cells by “missing 
self” recognition (Figure 1). 
Several nonrandomized prospective trials have demonstrated the potential efficacy of 
allogeneic stem cell transplantation in CLL; however even with reduced-intensity 
conditioning allogeneic stem cell transplantation is associated with significant morbidity 
and mortality. Nevertheless, it is a reasonable treatment option for poor-risk CLL patients. 
Allogeneic stem cell transplantation can overcome treatment resistance of poor-risk CLL 
defined as purine analogue refractoriness, early relapse after purine analogue combination 
therapy or autologous stem cell transplantation, and CLL with p53 deletion/mutation 
requiring treatment (Dreger et al., 2007). Nonmyeloablative allogeneic stem cell 
transplantation resulted in sustained remissions and prolonged survival in patients who 
had chemotherapy-refractory CLL (Sorror et al., 2008) and in high risk patients (Schetelig et 
al., 2008). Myeloablative allogeneic stem cell transplantation consistently results in a plateau 
in survival after 1 year, and the development of undetectable minimal residual disease 
(Pavletic et al., 2005). Evidence for graft-versus-leukemia in CLL can result in a complete 
and durable suppression of the leukemic clone (Ritgen et al., 2008; Rondón et al., 1996; 
Dreger et al., 2005; Farina et al., 2009; Sorror et al., 2005; Gribben et al., 2005). A prospective 
clinical trial is currently being performed in patients with high-risk CLL. This trial will finish 
in 2012 and will probably give us some guidance when and how to use allogeneic stem cell 
transplantation in poor-risk CLL.  
In summary, there is convincing evidence that allogeneic stem cell transplantation can 
provide long-term disease control and possibly cure in selected patients with CLL, 
including those with a biologically highly unfavorable risk profile. Even patients who 
relapsed after allogeneic transplant may achieve durable remission following donor 
lymphocyte infusion without further chemotherapy or radiation chemotherapy 
(Hoogendoorn et al., 2007; Schetelig et al., 2003; Delgado et al., 2006; Marina et al., 2010). 
This further highlights the capacity of the donor-derived immunity in eradicating tumors 
(Marina et al., 2010). 
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5.3 Immune modulating drugs 
Lenalidomide is a new immunomodulatory drug used in the treatment of CLL that is 
receiving considerable interest. It is a small molecular analog of thalidomide that was 
originally selected based on its ability to effectively inhibit tumor necrosis factor α (TNF-α) 
production. The mechanism of action of lenalidomide is complex and not yet fully 
understood. In CLL, lenalidomide has not a direct anti-tumor effect by inducing of 
apoptosis, but it has a significant anti-angiogenic and immune effects. It represents an 
exciting drug since it is able to eliminate CLL cells without immunosuppression.  
Lenalidomide is clinically used in combination with dexamethasone in patients with 
multiple myeloma who have received prior therapy, in myelodysplasic syndrome, and in 
addition, there are current clinical trials analyzing the therapeutic effect of this drug in other 
types of cancers. In CLL, lenalidomide is clinically effective as a single agent in relapsed and 
refractory patients (Ferrajoli et al., 2008 ; Chanan-Khan et al., 2006), and ongoing trials are 
demonstrating that lenalidomide is clinically active as first-line CLL therapy (Chen et al., 
2010). The responses achieved with lenalidomide are durable, even in patients with high-
risk disease, with poor risk cytogenetics and with high-risk cytogenetics [del(11q)(q22.3) or 
del(17p)(p13.1)] (Sher et al., 2010). 
The immunomodulatory mechanism of action of lenalidomide in CLL is poorly understood. 
Lenalidomide improves the humoral and cellular immune response of CLL patients (Figure 
5). Lenalidomide treatment is associated with a significant increase in immunoglobulin 
 
Fig. 5. Mechanism of action of lenalidomide in chronic lymphocytic leukemia. Lenalidomide 
does not have a direct cytotoxic effect on leukemia cells. Lenalidomide favors antigen 
presentation, activation, proliferation and functional activity of T cells. It also enhances 
Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) against rituximab-exposed 
leukemia cells. Other effects on angiogenic status remain to be elucidated. 
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levels. For instance, IgG levels were normalized in 7 out of 12 (58%) CLL patients with 
hypogammaglobulinemia (Badoux et al., 2009). Lenalidomide enhances antigen presentation 
to T cells (Aue et al., 2009; Chanan-Khan et al., 2006) and increases proliferation, activation 
and effector activity of T cells, which as mentioned before is impaired in CLL patients 
(Ramsay et al., 2008). Thalidomide and lenalidomide also have a significant 
immunomoudulatory effect on NK cells. In some experimental models, the antitumor effect 
of lenalidomide was mediated by NK cell stimulation (Awan et al., 2010). There is little 
information about the effect of lenalidomide on NK cells in vivo. Nevertheless, lenalidomide 
treatment increased the number of NK cells in CLL patients and increased Antibody-
Dependent Cell-Mediated Cytotoxicity against leukemia cells (Wu et al., 2008). 
Lenalidomide induces a unique and previously uncharacterized immune response called 
tumor flare reaction associated with immune mediated antitumor response. Tumor flare 
reaction with lenalidomide appears to be disease-specific to CLL, may reflect clinical 
manifestation of tumor cell activation and correlates with clinical response (Chanan-Khan et 
al., 2010). Combination of lenalidomide with rituximab may act synergistically if the timing 
and sequencing strategies are optimized. An exciting new therapeutic strategy may be 
targeting tumor cell with chemotherapy or monoclonal antibodies and the 
microenvironment with lenalidomide (Ramsay et al., 2009). 
6. Conclusion 
In spite of the existence of little information about the role of the immune system in the 
pathogenesis of CLL, the current data clearly support the hypothesis that the activation of 
the anti-tumor immune response, particularly in the early stages of the disease, may have a 
significant impact on tumor progression. However, CLL patients progressively acquire a 
wide variety of immune evasion mechanisms. As a result, patients acquire a progressive 
immunodeficiency status, which increases the incidence of opportunistic infections and the 
development of secondary neoplasias. Chemotherapy has been the keystone of treatment of 
CLL, but it is palliative and may worsen the immunodeficiency status of patients. 
Nevertheless, the development of drugs and therapeutic strategies that can either bypass the 
immune evasion mechanisms or rescue immune suppressor pathways may significantly 
benefit CLL patients. Thus, immunotherapy may provide curative treatment and may 
mitigate disease complications caused by the defects of the immune system observed in CLL 
patients. In this sense, monoclonal antibodies, allogeneic hematopoietic stem cell 
transplantation and immunomodulatory drugs have successfully been used in the treatment 
of CLL. Immune-based therapy represents an exciting mode of treatment since it may be 
able to eliminate leukemia cells without inducing immune suppression. The elucidation of 
the molecular and cellular events underlying the immune dysfunction in CLL is of key 
importance to further develop novel immune-based therapies. It is presumably that a 
deeper knowledge of the immune response in CLL may open new frontiers in the treatment 
of these patients. 
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